Trial Profile
A Prospective, Randomized, Double-Blind Comparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus in Adult Patients With Type 2 Diabetes Mellitus: The ELEMENT 2 Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Oct 2021
Price :
$35
*
At a glance
- Drugs Insulin glargine (Primary) ; Antihyperglycaemics
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms ELEMENT-2
- Sponsors Eli Lilly and Company
- 05 Oct 2018 Romania, Russia were the planned locations for this study.
- 05 Oct 2018 Results of an exploratory analyses from ELEMENT-2 and ELEMENT-5 presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
- 01 Aug 2018 Results from ELEMENT-1 and ELEMENT-2 studies published in the Diabetes Therapy